Skip to main content

Venn completes acquisition of Kinesis

Venn completes acquisition of Kinesis

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the completion of the acquisition of Kinesis Pharma BV.

Tony Richardson, Chief Executive Officer of Venn said: “We are pleased that the acquisition of Kinesis Pharma BV has completed as it has established Venn as a highly differentiated European Contract Research Organisation and is in line with Company’s strategy. We look forward to offering the complete range of services to our clients allowing us to establish earlier and longer lasting client relationships. We look forward to seeing the benefits of this acquisition in the near future.”